Author:
Begum Nasreen,George Jaish,Raghav Dinesh
Publisher
Jaypee Brothers Medical Publishing
Reference8 articles.
1. 1. Glorieux FH. Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics 2007;119(Suppl 2):S163–S165. DOI: 10.1542/peds.2006-2023I
2. 2. Michałus I, Nowicka Z, Pietras WA, et al. Pamidronate administration may result in anaemia in children with osteogenesis imperfecta. Arch Dis Child 2019;104(9):906–907. DOI: 10.1136/archdischild-2019-317467
3. 3. Szczepaniak-Kubat A, Kurnatowska O, Jakubowska-Pietkiewicz E, et al. Assessment of quality of life of parents of children with osteogenesis imperfecta. Adv Clin Exp Med 2012;21(1):99–104.
4. 4. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone 2011;49(1):42–49. DOI: 10.1016/j.bone.2011.01.014
5. 5. Gertz BJ, Holland SD, Kline WF, et al. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993;3(suppl 3):S13–S16. DOI: 10.1007/BF01623002